A Phase 3 study of ITI-1284 in Generalized Anxiety Disorder

Study Description

A Study to Evaluate the Effectiveness and Safety of ITI-1284 for the Treatment of Generalized Anxiety Disorder

Study Details

Registry ID:

NCT06701903

Conditions:

Generalized Anxiety Disorder

Phase:

Phase 2

Target Enrollment:

570 participants

Start Date:

November 21, 2024

Healthy Volunteers:

No

Study Locations (56 sites)

• Clinical Site
  BlagoevgradBulgaria, Bulgaria
• Clinical Site
  NišSerbia, Serbia
• Clinical Site
  SofiaBulgaria, Bulgaria
• Clinical Site
  KragujevacSerbia, Serbia
• Clinical Site
  KardzhaliBulgaria, Bulgaria
• Clinical Site
  PlovdivBulgaria, Bulgaria
• Clinical Site_3
  BelgradeSerbia, Serbia
• Clinical Site_2
  BelgradeSerbia, Serbia
• Clinical Site_4
  BelgradeSerbia, Serbia
• Clinical Site
  BelgradeSerbia, Serbia
• Clinical Site
  KovinSerbia, Serbia
• Clinical Site
  PlevenBulgaria, Bulgaria
• Clinical Site
  Novi KneževacSerbia, Serbia
• Clinical Site
  TargovishteBulgaria, Bulgaria
• Clinical Site
  RousseBulgaria, Bulgaria
• Clinical Site
  BratislavaSlovakia, Slovakia
• Clinical Site
  Rimavská SobotaSlovakia, Slovakia
• Clinical Site
  Vranov nad TopľouSlovakia, Slovakia
• Clinical Site
  SvidníkSlovakia, Slovakia
• Clinical Site
  LesznoPoland, Poland
• Clinical Site
  BydgoszczPoland, Poland
• Clinical Site
  TorunPoland, Poland
• Clinical Site
  GdanskPoland, Poland
• Clinical Site
  BialystokPoland, Poland
• Clinical Site
  HelsinkiFinland, Finland
• Clinical Site
  TampereFinland, Finland
• Clinical Site
  KuopioFinland, Finland
• Clinical Site
  OuluFinland, Finland
• Clinical Site
  Boston, MassachusettsUnited States, United States
• Clinical Site
  Farmington, ConnecticutUnited States, United States
• Clinical Site
  Miami, FloridaUnited States, United States
• Clinical Site
  Brooklyn, New YorkUnited States, United States
• Clinical Site
  Staten Island, New YorkUnited States, United States
• Clinical Site
  Media, PennsylvaniaUnited States, United States
• Cinical Site
  Orlando, FloridaUnited States, United States
• Clinical Site
  Tampa, FloridaUnited States, United States
• Clinical Site
  Gainesville, FloridaUnited States, United States
• Clinical Site
  Buffalo, New YorkUnited States, United States
• Clinical Site
  Decatur, GeorgiaUnited States, United States
• Clinical Site
  Columbus, OhioUnited States, United States
• Clinical Site
  Birmingham, AlabamaUnited States, United States
• Clinical Site
  Flowood, MississippiUnited States, United States
• Clinical Site
  Chicago, IllinoisUnited States, United States
• Clinical Site
  Little Rock, ArkansasUnited States, United States
• Clinical Site
  Rogers, ArkansasUnited States, United States
• Clinical Site
  Dallas, TexasUnited States, United States
• Clinical Site
  Oklahoma City, OklahomaUnited States, United States
• Clinical Site
  Oceanside, CaliforniaUnited States, United States
• Clinical Site
  Upland, CaliforniaUnited States, United States
• Clinical Site
  Los Angeles, CaliforniaUnited States, United States
• Clinical Site
  Culver City, CaliforniaUnited States, United States
• Clinical Site
  Sherman Oaks, CaliforniaUnited States, United States
• Clinical Site_2
  Encino, CaliforniaUnited States, United States
• Clinical Site
  Encino, CaliforniaUnited States, United States
• Clinical Site
  Walnut Creek, CaliforniaUnited States, United States
• Clinical Site
  Bellevue, WashingtonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →